* LifeMD Inc LFMD.OQ LFMD.O is expected to show a rise
in
quarterly revenue when it reports results on March 11 for the
period ending December 31 2023
* The New York City-based company is expected to report a
44.0% increase in revenue to $40.494 million from $28.12 million
a year ago, according to the mean estimate from 5 analysts,
based on LSEG data.The company's guidance on November 8 2023,
for the period ended December 31, was for revenue between $40.00
million and $41.00 million.
* LSEG's mean analyst estimate for LifeMD Inc is for a loss
of 14
cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for LifeMD Inc
is
$11.00, above its last closing price of $7.90.
The company's guidance on November 8 2023 for the period ended
December 31 was for Earnings before Interest, Taxes,
Depreciation and Amortization of between USD40 million and USD4
million.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2023 -0.15 -0.15 -0.20 Missed -29
Jun. 30 2023 -0.10 -0.10 -0.23 Missed -122.6
Mar. 31 2023 -0.16 -0.16 -0.15 Beat 6.3
Dec. 31 2022 -0.18 -0.18 -0.40 Missed -122.2
Sep. -0.30 -0.28 -0.26 Beat 8.8
30 2022
Jun. 30 2022 -0.35 -0.35 -0.45 Missed -28.6
Mar. 31 2022 -0.41 -0.36 -0.46 Missed -26
Dec. 31 2021 -0.42 -0.42 -0.62 Missed -45.9
This summary was machine generated March 8 at 20:28 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)